Has Philip Sager received payments from drug or device companies?

Yes. Drug and device makers reported $675,391 in general payments to Philip Sager across 81 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Philip Sager did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Philip Sager come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Philip Sager

Cardiovascular Disease · San Francisco, CANPI 1427487149

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $673,464 of the $675,391 with a category attached, or 99.7%. 12 manufacturers reported payments, led by Daiichi Sankyo Inc. at 28.2% of the total. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$675,391in general payments, 2019–2025

Across 81 payments — averaging $8338.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$190K
Eli Lilly$181K
Syndax Pharmaceuticals, Inc.$139K
Jazz Pharmaceuticals Inc.$56K
Acadia Pharmaceuticals Inc$30K
Amarin Pharma, Inc.$26K
plus $53K from 6 others

$38,700in research payments, 2019–2025

Across 1 payment — averaging $38,700 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$39K

What the payments were for

Consulting fees$673,464100%
Travel & lodging$1,8590%
Food & beverage$680%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	14	$190,128
Eli Lilly	25	$181,291
Syndax Pharmaceuticals, Inc.	2	$139,305
Jazz Pharmaceuticals Inc.	14	$55,868
Acadia Pharmaceuticals Inc	7	$30,074
Amarin Pharma, Inc.	5	$25,883
Otsuka Pharmaceutical Co., Ltd.	3	$19,250
GSK	4	$17,640
Vertex	1	$7,770
Amgen	2	$3,645
Mirati Therapeutics, Inc.	2	$2,363
AbbVie	2	$2,175

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUPLAZID$30,074
Vascepa$25,883
JZP-441$17,875
KRAZATI$2,363

How this compares

$675,391 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in San Francisco

Javid MoslehiSan Francisco$307K
Tony ChouSan Francisco$301K
Lloyd KleinSan Francisco$149K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →